Literature DB >> 21562737

Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Amal Alachkar1, Jonathan M Brotchie, Owen T Jones.   

Abstract

The changes in the mRNA levels of α(2A) and α(2C) adrenoceptors were investigated in unilateral 6-OHDA-lesioned rat model of Parkinson's disease and L: -DOPA-induced dyskinesia using in situ hybridization. In the untreated 6-OHDA-lesioned rats, α(2A) expression was elevated in the locus coeruleus (160 ± 8% and 142 ± 8% in lesioned and unlesioned sides compared to the comparable side in sham-operated rats). Following long-term (21 days, twice daily) treatment with L: -DOPA (25 mg/kg L: -DOPA methyl ester plus benserazide 6.25 mg/kg) in 6-OHDA-lesioned rats, levels of α(2A) adrenoceptor mRNA in the locus coeruleus were decreased, compared to the 6-OHDA-lesioned rats, returning to the levels of α(2A) mRNA in the sham-operated rats. α(2A) adrenoceptor expression was not changed in other brain regions in any treatment group. There was no change in α(2C) expression in the rostral or caudal striatum in which the highest density of α(2C) mRNA is present. In conclusion, the data presented in this study demonstrate an increase in α(2A) adrenoceptor mRNA in the locus coeruleus in the 6-OHDA-lesioned rat model of Parkinson's disease. In addition, the data show that repeated treatment with L: -DOPA in 6-OHDA-lesioned rats, which induces dyskinesia, restores α(2A) mRNA levels. These changes of α(2A) mRNA expression, observed in the locus coeruleus, might be of importance to basal ganglia transmission and motor function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562737     DOI: 10.1007/s12031-011-9539-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  57 in total

1.  Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.

Authors:  M A Silverdale; S McGuire; A McInnes; A R Crossman; J M Brotchie
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

2.  Autoradiographic studies of central alpha 2A- and alpha 2C-adrenoceptors in the rat using [3H]MK912 and subtype-selective drugs.

Authors:  S Uhlén; J Lindblom; A Johnson; J E Wikberg
Journal:  Brain Res       Date:  1997-10-03       Impact factor: 3.252

3.  The alpha2C-adrenoceptor modulates GABA release in mouse striatum.

Authors:  Weilie Zhang; Gregory A Ordway
Journal:  Brain Res Mol Brain Res       Date:  2003-04-10

4.  Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study.

Authors:  A P Nicholas; V Pieribone; T Hökfelt
Journal:  J Comp Neurol       Date:  1993-02-22       Impact factor: 3.215

5.  Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain.

Authors:  C L Boyajian; S E Loughlin; F M Leslie
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

6.  alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata.

Authors:  Amal Alachkar; Jonathan Brotchie; Owen T Jones
Journal:  Neurosci Lett       Date:  2005-12-13       Impact factor: 3.046

7.  Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

Authors:  Andrzej Dekundy; Martin Lundblad; Wojciech Danysz; M Angela Cenci
Journal:  Behav Brain Res       Date:  2007-01-23       Impact factor: 3.332

8.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

9.  Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Authors:  Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurster; Steven G McGuire; Susan H Fox; Alan R Crossman; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

Review 10.  Psychotic symptoms in Parkinson's disease: pathophysiology and management.

Authors:  J L W Bosboom; E Ch Wolters
Journal:  Expert Opin Drug Saf       Date:  2004-05       Impact factor: 4.250

View more
  5 in total

1.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

2.  Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.

Authors:  Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-09       Impact factor: 9.236

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.

Authors:  Cristina Miguelez; Asier Aristieta; Maria Angela Cenci; Luisa Ugedo
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

5.  Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases.

Authors:  Kathrin Janitzky
Journal:  Front Neurol       Date:  2020-05-12       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.